UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ Preliminary
Proxy Statement
☐ Confidential, for Use of the
Commission Only (as permitted by Rule
14a-6(e)(2))
☐ Definitive
Proxy Statement
☒
Definitive
Additional Materials
☐
Soliciting
Material Pursuant to Rule 14a-12
ENDRA LIFE SCIENCES INC.
(Name
of Registrant as Specified in its Charter)
(Name
of Person(s) Filing Proxy Statement, if Other Than the
Registrant)
Payment of Filing Fee (Check the appropriate box):
☒
No
fee required.
☐
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
(1)
Title
of each class of securities to which transaction applies:
N/A
(2)
Aggregate
number of securities to which transaction applies: N/A
(3)
Per
unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
N/A
(4)
Proposed
maximum aggregate value of transaction:
☐
Fee
paid previously with preliminary materials.
☐
Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date
of its filing.
(1)
Amount
Previously Paid: N/A
(2)
Form,
Schedule or Registration Statement No.: N/A
3600 Green Court, Suite 350
Ann Arbor, Michigan 48105
August
10, 2020
To the
Stockholders of ENDRA Life Sciences Inc. (the
“Company”):
The
Company has extended the expiration date for its current Consent
Solicitation, currently set to expire on August 13, 2020, to
5:00 p.m. Eastern Time on August
20, 2020, subject to early termination or extension in the
Company’s discretion, to allow more opportunity for
stockholders to submit consents on the proposal described in the
Company’s definitive Consent Solicitation Statement filed
with the Securities and Exchange Commission (the “SEC”)
on August 3, 2020, which is a proposal to approve the potential
issuance of shares of the Company’s common stock upon the
exercise of certain warrants at reduced exercise prices, in
compliance with Nasdaq Stock Market Rule 5635(d).
Only
stockholders of record of the Company’s common stock and
preferred stock as of the close of business on July 7, 2020 are
entitled to submit Action by Written Consent forms in connection
with the Consent Solicitation. All stockholders who have previously
voted in the Consent Solicitation do not need to re-vote or take
any other action; executed written consents delivered to the
Company are not revocable.
No
changes have been made in the proposal for which consent is
solicited as described in the Consent Solicitation. THE COMPANY
STRONGLY ADVISES ALL OF ITS STOCKHOLDERS TO READ THE CONSENT
SOLICITATION STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION.
SUCH CONSENT SOLICITATION STATEMENT IS AVAILABLE AT NO CHARGE ON
THE SEC’S WEBSITE AT WWW.SEC.GOV. In addition, copies of the
Consent Solicitation Statement may be obtained free of charge by
accessing the Company’s website at
investors.endrainc.com/NDRA/sec_filings or by contacting the
Company at (734) 335-0468 or by mail to 3600 Green Court, Suite
350, Ann Arbor, MI 48105.
Sincerely,
/s/
David Wells
David
Wells
Chief Financial Officer and Secretary
